Acute promyelocytic leukemia (APL)

Comparison between children and adults

Anna Maria Testi, Mariella D'Angiò, Franco Locatelli, Andrea Pession, Francesco Lo Coco

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed since the introduction of all trans retinoic acid (ATRA) therapy. Based on the results of several multicenter trials, the current recommendations for the treatment of patients with APL include ATRA and anthracycline-based chemotherapy for the remission induction and consolidation, and ATRA combined with low-dose chemotherapy for maintenance. This has improved the prognosis of APL by increasing the complete remission (CR) rate, actually > 90%, decreasing the induction deaths and by reducing the relapse rate, leading to cure rates nowadays exceeding 80% considering both adults and children.1-9 More recently the combination of ATRA and arsenic trioxide (ATO) as induction and consolidation therapy has been shown to be at least not inferior and possibly superior to ATRA plus chemotherapy in adult patients with APL conventionally defined as non-high risk (Sanz score).10 Childhood APL has customarily been treated on adult protocols. Data from several trials have shown that the overall outcome in pediatric APL appears similar to that reported for the adult population; however, some clinical and therapeutic aspects differ in the two cohorts which require some important considerations and treatment adjustments.

Original languageEnglish
Article numbere2014032
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume6
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Consolidation Chemotherapy
Therapeutics
Remission Induction
Drug Therapy
Anthracyclines
Multicenter Studies
Maintenance
Pediatrics
Recurrence
Population

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Cite this

Acute promyelocytic leukemia (APL) : Comparison between children and adults. / Testi, Anna Maria; D'Angiò, Mariella; Locatelli, Franco; Pession, Andrea; Coco, Francesco Lo.

In: Mediterranean Journal of Hematology and Infectious Diseases, Vol. 6, No. 1, e2014032, 2014.

Research output: Contribution to journalArticle

@article{f2c3f7ffcb43490f909e964a02fb6555,
title = "Acute promyelocytic leukemia (APL): Comparison between children and adults",
abstract = "The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed since the introduction of all trans retinoic acid (ATRA) therapy. Based on the results of several multicenter trials, the current recommendations for the treatment of patients with APL include ATRA and anthracycline-based chemotherapy for the remission induction and consolidation, and ATRA combined with low-dose chemotherapy for maintenance. This has improved the prognosis of APL by increasing the complete remission (CR) rate, actually > 90{\%}, decreasing the induction deaths and by reducing the relapse rate, leading to cure rates nowadays exceeding 80{\%} considering both adults and children.1-9 More recently the combination of ATRA and arsenic trioxide (ATO) as induction and consolidation therapy has been shown to be at least not inferior and possibly superior to ATRA plus chemotherapy in adult patients with APL conventionally defined as non-high risk (Sanz score).10 Childhood APL has customarily been treated on adult protocols. Data from several trials have shown that the overall outcome in pediatric APL appears similar to that reported for the adult population; however, some clinical and therapeutic aspects differ in the two cohorts which require some important considerations and treatment adjustments.",
author = "Testi, {Anna Maria} and Mariella D'Angi{\`o} and Franco Locatelli and Andrea Pession and Coco, {Francesco Lo}",
year = "2014",
doi = "10.4084/MJHID.2014.032",
language = "English",
volume = "6",
journal = "Mediterranean Journal of Hematology and Infectious Diseases",
issn = "2035-3006",
publisher = "Universita Cattolica del Sacro Cuore",
number = "1",

}

TY - JOUR

T1 - Acute promyelocytic leukemia (APL)

T2 - Comparison between children and adults

AU - Testi, Anna Maria

AU - D'Angiò, Mariella

AU - Locatelli, Franco

AU - Pession, Andrea

AU - Coco, Francesco Lo

PY - 2014

Y1 - 2014

N2 - The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed since the introduction of all trans retinoic acid (ATRA) therapy. Based on the results of several multicenter trials, the current recommendations for the treatment of patients with APL include ATRA and anthracycline-based chemotherapy for the remission induction and consolidation, and ATRA combined with low-dose chemotherapy for maintenance. This has improved the prognosis of APL by increasing the complete remission (CR) rate, actually > 90%, decreasing the induction deaths and by reducing the relapse rate, leading to cure rates nowadays exceeding 80% considering both adults and children.1-9 More recently the combination of ATRA and arsenic trioxide (ATO) as induction and consolidation therapy has been shown to be at least not inferior and possibly superior to ATRA plus chemotherapy in adult patients with APL conventionally defined as non-high risk (Sanz score).10 Childhood APL has customarily been treated on adult protocols. Data from several trials have shown that the overall outcome in pediatric APL appears similar to that reported for the adult population; however, some clinical and therapeutic aspects differ in the two cohorts which require some important considerations and treatment adjustments.

AB - The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed since the introduction of all trans retinoic acid (ATRA) therapy. Based on the results of several multicenter trials, the current recommendations for the treatment of patients with APL include ATRA and anthracycline-based chemotherapy for the remission induction and consolidation, and ATRA combined with low-dose chemotherapy for maintenance. This has improved the prognosis of APL by increasing the complete remission (CR) rate, actually > 90%, decreasing the induction deaths and by reducing the relapse rate, leading to cure rates nowadays exceeding 80% considering both adults and children.1-9 More recently the combination of ATRA and arsenic trioxide (ATO) as induction and consolidation therapy has been shown to be at least not inferior and possibly superior to ATRA plus chemotherapy in adult patients with APL conventionally defined as non-high risk (Sanz score).10 Childhood APL has customarily been treated on adult protocols. Data from several trials have shown that the overall outcome in pediatric APL appears similar to that reported for the adult population; however, some clinical and therapeutic aspects differ in the two cohorts which require some important considerations and treatment adjustments.

UR - http://www.scopus.com/inward/record.url?scp=84902596789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902596789&partnerID=8YFLogxK

U2 - 10.4084/MJHID.2014.032

DO - 10.4084/MJHID.2014.032

M3 - Article

VL - 6

JO - Mediterranean Journal of Hematology and Infectious Diseases

JF - Mediterranean Journal of Hematology and Infectious Diseases

SN - 2035-3006

IS - 1

M1 - e2014032

ER -